Compound class:
Antibody
Comment: CIS43 is a human monoclonal antibody directed against the P. falciparum circumsporozoite protein (PfCSP) [3]. The structure has not been formally disclosed and has not been curated by IMGT.
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. |
| No information available. |
Summary of Clinical Use  |
| Phase 1 and 2 clinical trials to evaluate the the safety, tolerability, and efficacy of CIS43LS (modified to be longer acting [4]) against P. falciparum infection have begun. Results from Phase 1 NCT04206332 have been published, with no safety concerns identified and indicating that CIS43LS prevents malaria after controlled infection [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04329104 | Anti-malaria MAb in Mali | Phase 2 Interventional | National Institute of Allergy and Infectious Diseases (NIAID) | ||
| NCT04206332 | Trial to Evaluate CIS43LS in Healthy Adults | Phase 1 Interventional | National Institutes of Health Clinical Center (CC) | 2 | |
| Pharmacokinetics |
| Elimination |
| The half-life of CIS43LS is 56 days [2]. |
